At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ERNA Eterna Therapeutics Inc.
Market Closed 05-08 16:00:00 EDT
7.53
-0.29
-3.71%
盘后7.31
-0.22-2.92%
19:59 EDT
High8.11Low6.39Vol1.46M
Open7.74D1 Closing7.82Amplitude22.02%
Mkt Cap8.78MTradable Cap6.16MTotal Shares1.17M
T/O10.85MT/O Rate178.59%Tradable Shares817.98K
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Ernexa Therapeutics initiated with a Buy at Brookline
TIPRANKS  ·  05-08 05:58
Ernexa Therapeutics initiated with a Buy at Brookline
Ernexa Therapeutics announces new ERNA-101 preclinical data
TIPRANKS  ·  05-07 12:27
Ernexa Therapeutics announces new ERNA-101 preclinical data
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:34 AM
Reuters  ·  05-06
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:34 AM
Ernexa reports ERNA-101 plus PD-1 blockade clears tumors in ovarian cancer models
Reuters  ·  05-06
Ernexa reports ERNA-101 plus PD-1 blockade clears tumors in ovarian cancer models
NASDAQ TRADE HALT HALT NEWS PENDING AT 03:28 AM
Reuters  ·  05-03
NASDAQ TRADE HALT HALT NEWS PENDING AT 03:28 AM
Ernexa Therapeutics Announces 1-for-25 Reverse Stock Split
GlobeNewswire  ·  04-30
Ernexa Therapeutics Announces 1-for-25 Reverse Stock Split
Ernexa Therapeutics authorizes 1-for-10 to 1-for-25 reverse stock split to meet Nasdaq bid rule
Reuters  ·  04-13
Ernexa Therapeutics authorizes 1-for-10 to 1-for-25 reverse stock split to meet Nasdaq bid rule
Ernexa Therapeutics files draft information statement for potential reverse stock split
Reuters  ·  04-02
Ernexa Therapeutics files draft information statement for potential reverse stock split
Ernexa Therapeutics Highlights Key Catalysts as Company Advances Toward First-in-Human Clinical Trials in 2026
GlobeNewswire  ·  03-31
Ernexa Therapeutics Highlights Key Catalysts as Company Advances Toward First-in-Human Clinical Trials in 2026
Ernexa Therapeutics faces Nasdaq delisting notice after bid price falls below $1 for 30 days
Reuters  ·  03-21
Ernexa Therapeutics faces Nasdaq delisting notice after bid price falls below $1 for 30 days
Ernexa Therapeutics files $50M mixed securities shelf
TIPRANKS  ·  03-16
Ernexa Therapeutics files $50M mixed securities shelf
BRIEF-Ernexa Therapeutics Inc - May Offer Up To $50 Million Of Securities - SEC Filing
Reuters  ·  03-16
BRIEF-Ernexa Therapeutics Inc - May Offer Up To $50 Million Of Securities - SEC Filing
Ernexa Therapeutics Inc - May Offer up to $50 Mln of Securities - SEC Filing
THOMSON REUTERS  ·  03-16
Ernexa Therapeutics Inc - May Offer up to $50 Mln of Securities - SEC Filing
Ernexa Therapeutics FY 2025 net loss narrows 68% to USD 14.08 million
Reuters  ·  03-14
Ernexa Therapeutics FY 2025 net loss narrows 68% to USD 14.08 million
Ernexa Therapeutics CEO Sanjeev Luther to Join Virtual Investor Closing Bell Series Webcast
Reuters  ·  02-20
Ernexa Therapeutics CEO Sanjeev Luther to Join Virtual Investor Closing Bell Series Webcast
10% Owner Charles Cherington Reports Acquisition of Ernexa Therapeutics Inc. Common Shares
Reuters  ·  02-18
10% Owner Charles Cherington Reports Acquisition of Ernexa Therapeutics Inc. Common Shares
Ernexa Therapeutics Announces Issuance of Warrants in $10.5 Million Public Offering
Reuters  ·  02-12
Ernexa Therapeutics Announces Issuance of Warrants in $10.5 Million Public Offering
Ernexa Therapeutics prices 21M shares at 50c in public offering
TIPRANKS  ·  02-06
Ernexa Therapeutics prices 21M shares at 50c in public offering
Ernexa Therapeutics Announces Pricing of $10.5 Million Public Offering
GlobeNewswire  ·  02-06
Ernexa Therapeutics Announces Pricing of $10.5 Million Public Offering
Ernexa Therapeutics Participates in Virtual Investor “What This Means” Segment Highlighting Recent Successful Pre-IND Meeting with U.S. FDA
GlobeNewswire  ·  02-03
Ernexa Therapeutics Participates in Virtual Investor “What This Means” Segment Highlighting Recent Successful Pre-IND Meeting with U.S. FDA

Introduction

Company Name.
Eterna Therapeutics Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Eterna Therapeutics Inc., a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
Issue price:
--